TAC T-cells for the Treatment of HER2-positive Solid Tumors

NCT04727151 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by Sponsor for commercial reasons

Conditions

HER2 Positive Gastric Cancer
Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions

BIOLOGICAL: TAC01-HER2
BIOLOGICAL: TAC01-HER2 plus pembrolizumab

Sponsor

Triumvira Immunologics, Inc.

Collaborators

[object Object]